Ensure Surgery Immunonutrition Shake

Phase 1Small molecule

Ensure Surgery Immunonutrition Shake is one of 38 small molecule programs targeting Ischemia. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

IschemiaActive, not recruiting

Critical Limb IschemiaRecruiting

IschemiaPhase 1

Active, not recruiting

Critical Limb IschemiaPhase 1

Recruiting

Competition

Competitive Landscape

159 competitors in Ischemia

#DrugCompanyPhaseTrials

Adenocard

Astellas

Phase 3

3 2

Isordil

AstraZeneca

Phase 3

1 3

Garamycin

SSchering-Plough

Phase 3

1 4

Procardia

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

1 5

Flagyl

DDePuy Orthopaedics

Phase 3

1 6

Osmitrol

BB. Braun Medical Inc.

Phase 3

1 7

Cardizem

BBausch Health Americas, Inc.

Phase 3

1 8

Avlosulfon

AAlmirall, S.A.

Phase 3

1 9

Remodulin

United Therapeutics

Phase 3

2 10

Ixmyelocel-T

VVericel Corporation

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1Recruiting

Critical Limb Ischemia

NCT03529019

Clinical

Trials by Indication[1]

Critical Limb Ischemia1 trial

Perioperative Nutritional Optimization in Patients With Critical Limb Ischemia

Recruiting·BBoston Medical Center·Phase 1·NCT03529019·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Ensure Surgery Immunonutrition Shake. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ensure Surgery Immunonutrition Shake compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ensure Surgery Immunonutrition Shake. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Boston Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: BBoston Medical Center

Ensure Surgery Immunonutrition Shake

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Critical Limb Ischemia1 trial

References

Drug Info

Quick Facts

Related News